Chemotherapy Induced Nausea And Vomiting Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

Industry Outlook

The chemotherapy induced nausea and vomiting treatment market is set to reach US$ 4,568.8 Mn by 2030 from US$ 2,592.3 Mn in 2021 showcasing progressive growth at a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2022 to 2030. As per the latest statistics provided by the National Cancer Institute in 2018 approximately 1,735,350 new cancer cases will be reported with an estimation of 609,640 people dying with cancer. Technological advancement in the diagnostic kits have resulted in early cancer diagnosis which helps the physician to enroll the patient on chemotherapy treatment immediately. It is important to understand that 90% patient receiving chemotherapy suffer with nausea and vomiting.

There has been a shift in the treatment regimen, earlier dopamine antagonist in combination with corticosteroid were prescribed as antiemetic agents, which have been replaced by drug combination of serotonin receptor antagonist and NK1 receptor antagonist. Rising prevalence of cancer and growing popularity of chemotherapy as treatment option is responsible for the dominance of North America in CINV treatment market. Developing healthcare infrastructure and competition exerted by local generic drug manufacturers stimulate the CINV market growth in Asia Pacific.

Excellent pharmacokinetic properties to boost the sale of NK1 receptor antagonist during the forecast period

Serotonin receptor antagonist are leading the drug class market for chemotherapy induced nausea and vomiting treatment on account of its excellent antiemetic activity in cancer patients suffering with acute nausea. Drugs such as palonosetron, granisetron and dolasetron are available as oral, parenteral and transdermal patches, catering the need of patients belonging to all age groups. Multiple studies conducted in the clinical trials have suggested the combined therapy of dopamine antagonist with benzodiazepine or corticosteroid to be effective in treating the patients suffering with refractory CINV. NK1 receptor antagonist have shown excellent clinical outcomes in the treatment of delayed nausea with outstanding pharmacokinetic properties. They are prescribed in combination with 5HT3 receptor antagonist e.g. Alkynzeo (Helsinn Healthcare) and is set to register tremendous growth during the forecast period.

Chemotherapy to drive the CINV treatment market in North America

North America is currently leading the chemotherapy induced nausea and vomiting treatment market with 38% regional share. Rising prevalence of patients suffering with cancer, growing popularity of chemotherapy as treatment option among the patient population drives the CINV market in North America. Major players such as Sanofi-Aventis and Helsinn healthcare are striving to manufacture effective antiemetic drugs to treat CINV in North America. Existence of well-developed healthcare infrastructure, and adherence to treatment guidelines steers the CINV market in Europe. Competition exerted by the local players manufacturing generic drugs and supportive regulatory environment propel the CINV market growth in Asia Pacific region. Latin America and Middle East and Africa serve as lucrative market due to rising awareness of chemotherapy induced nausea and vomiting in healthcare professionals and rise in per capita income.

Latest market trends and quantitative analysis are performed to understand the market dynamics existing in the chemotherapy induced nausea and vomiting treatment market. Vital information regarding the inorganic business strategies such as mergers and collaboration between pharmaceutical players are highlighted in this report. In the product portfolio section quick insight regarding the diverse brands in different drug combinations is obtained. The major players dominating the chemotherapy induced nausea and vomiting treatment market are Baxter Pharmaceuticals, Eisai, Inc., Helsinn Healthcare, GlaxoSmithkline, Plc, Merck & Co. Inc., ProStrakan, Inc., Pfizer, Inc., Sanofi-Aventis, Solvay Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Chemotherapy Induced Nausea And Vomiting Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Chemotherapy Induced Nausea And Vomiting Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

• Serotonin Receptor Antagonist
• Ondansetron
• Granisetron
• Dolasetron
• Palonosetron
• Neurokinin NK1 Receptor Antagonist
• Aprepitant
• Casopitant
• Netupitant
• Dopamine Antagonist
• Metoclopramide
• Prochlorperazine
• Benzodiazepine
• Lorazepam
• Others (Corticosteroids, Cannabinoids)

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Chemotherapy Induced Nausea And Vomiting Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Chemotherapy Induced Nausea And Vomiting Treatment market?
• Which is the largest regional market for Chemotherapy Induced Nausea And Vomiting Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Chemotherapy Induced Nausea And Vomiting Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Chemotherapy Induced Nausea And Vomiting Treatment market worldwide?

This product will be delivered within 2 business days.